Bonehealth in children and adolescents with hematologic/oncologic diseases
Recruiting
- Conditions
- complete spectrum of paediatric oncologic diseases.chronic haematological diseases (sickle cell, thalassemia)C00-C97D55-D59Malignant neoplasmsHaemolytic anaemias
- Registration Number
- DRKS00003636
- Lead Sponsor
- Abteilung für Hämatologie und OnkologieKinderklinik IIIUniversitätsklinikum Essen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
oncologic/hematologic disease
Exclusion Criteria
symptomatic anemia
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Risk of osseous morbidity in cancer survivors <br>Risk of osseous morbidity in patients with chronic haematological disease
- Secondary Outcome Measures
Name Time Method Influence of life style parameters on bone health.<br>correlation of osteocalcin levels and osseous morbidity.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What biomarkers predict bone mineral density loss in pediatric oncology patients with thalassemia or sickle cell disease?
How do chemotherapy-induced myelosuppression and radiation therapy impact bone remodeling markers in DRKS00003636 participants?
What molecular pathways (e.g., RANKL, Wnt) are associated with osteoporosis risk in hematologic malignancy survivors?
Compare bone health outcomes between hydroxyurea-treated sickle cell patients and those receiving bisphosphonate therapy in observational cohorts.
What long-term skeletal complications arise in pediatric cancer survivors enrolled in DRKS00003636 compared to standard-of-care populations?